TSX Venture Exchange Stock Maintenance Bulletins

TSX VENTURE COMPANIES

FLUROTECH LTD. ("TEST.H")
[formerly FluroTech Ltd. ("TEST")]
BULLETIN TYPE: Transfer and New Addition to NEX, Symbol Change, Resume Trading
BULLETIN DATE: October 26, 2023
TSX Venture Tier 2 Company

Effective at the opening, Monday, October 30, 2023 , the securities of FluroTech Ltd., (the "Company") will resume trading.  Further to the Exchange Bulletin dated April 17, 2023 , a news release was issued on October 6, 2023 , announcing that the Company will not be proceeding with its proposed transaction.  The transaction contemplated would have constituted a Reverse Takeover as defined under Exchange Policy 5.2.

In accordance with TSX Venture Policy 2.5, the Company has not maintained the requirements for a TSX Venture Tier 2 company.  Therefore, effective at the opening on Monday, October 30, 2023 , the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Calgary to NEX.

As of October 30, 2023 the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies.

The trading symbol for the Company will change from TEST to TEST.H.  There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital.  The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market.

________________________________________

Right Season Investments Corp. ("LITT")
BULLETIN TYPE:  Consolidation
BULLETIN DATE: October 26, 2023
TSX Venture Tier 2 Company

Pursuant to a resolution passed by the shareholders of the Company on October 20, 2023 , the Company has consolidated its capital on a seventy (70) old for one (1)  new basis.  The name of the Company has not been changed.

Effective at the opening October 30, 2023 , the shares of Right Season Investments Corp. will commence trading on TSX Venture Exchange on a consolidated basis. The Company is classified as a 'Financial Services - Investment Companies and Funds' company.

Post - Consolidation

Capitalization:                          Unlimited   shares with no par value of which

2,262,956   shares are issued and outstanding

Escrow                                     Nil   shares are subject to escrow

Transfer Agent:                        Endeavor Trust Corporation

Trading Symbol:                       LITT                  ( UNCHANGED )

CUSIP Number:                       76658Q206 (NEW)

________________________________________

STALLION URANIUM CORP. ("STUD ")
[formerly STALLION DISCOVERIES CORP. ("STUD ")]
BULLETIN TYPE:  Name Change
BULLETIN DATE: October 26, 2023
TSX Venture Tier 2 Company

Pursuant to a resolution passed by directors on October 11, 2023 , the Company has changed its name as follows.  There is no consolidation of capital.

Effective at the opening October 30, 2023 , the common shares of  Stallion Uranium Corp. will commence trading on TSX Venture Exchange, and the common shares of Stallion Discoveries Corp. will be delisted.  The Company is classified as a 'Mining' company.

Capitalization:                                     Unlimited  shares with no par value of which

109,381,286  shares are issued and outstanding

Escrow:                                               nil  common shares

Transfer Agent:                                   Endeavor Trust Corporation

Trading Symbol:                                  STUD                   ( UNCHANGED )

CUSIP Number:                                  852919109            ( NEW )

________________________________________

Sucro Limited ("SUG")
B ULLETIN TYPE: New Listing-Shares
BULLETIN DATE: October 26, 2023
TSX Venture Tier 2 Company

The Prospectus of Sucro Limited ("Sucro") dated October 19, 2023 (the "Prospectus") has been filed with and accepted by the Ontario , Alberta , British Columbia Manitoba, New Brunswick , Newfoundland and Labrador , Nova Scotia , Prince Edward Island and Saskatchewan Securities Commissions, effective October 23, 2023 , pursuant to the provisions of the Ontario , Alberta , British Columbia Manitoba, New Brunswick , Newfoundland and Labrador , Nova Scotia , Prince Edward Island and Saskatchewan Securities Acts.

The subordinate voting shares (the "SVS") of the Company will be listed and admitted to trading on TSX Venture Exchange, on the effective dates stated below. Each Proportionate Voting Shares ("PVS") is convertible into one hundred (100) SVS. Only the SVS will be listed on the Exchange.

The gross proceeds to be received by the Company for the Offering Are C$15,004,000 , being 1,364,000 SVS at C$11 per SVS, plus up to an additional 15% if over-allotment option is exercised in full.

Listing Date:                  At the close of business ( 5:01 p.m. EDT ) on Friday, October 27, 2023 .

Commence Date:          The SVS will commence trading on TSX Venture Exchange at the opening on Monday, October 30, 2023 , upon confirmation of closing.

The closing of the public offering is scheduled to occur before the market opening on Monday, October 30, 2023 . A further notice will be issued upon receipt of closing confirmation.

For further information, please refer to the Company's Prospectus dated October 19, 2023 available on SEDAR+ and to the Company's news releases dated October 23, 2023 .

Corporate Jurisdiction: Cayman Islands

Capitalization:

Authorized:       490,000,000 SVS and 1,000,000 PVS

with a par value of US$0.0001 per SVS and US$0.001 per PVS, of which

Issued and Outstanding: 6,528,421 SVS and 167,189 PVS (not listed)

Escrowed Securities:     1,153,244 SVS and 167,189 PVS of which

115,324 SVS and 16,718 PVS are released as at the date of this bulletin

Transfer Agent:             Odyssey Trust Company

Trading Symbol: SUG

CUSIP Number: G8544S107

The Company is classified as a "Sugar Manufacturing" company (NAICS: 311310).

Company Contact:                    Stefano D'Aniello, CFO

Company Address:                   2020 Ponce de Leon Blvd., Suite 1204 Coral Gables, Florida 33134 USA Company Phone Number:             (305) 901-1322

Company Email Address: sdaniello@sucro.us

Company Website: www.sucro.us

________________________________________

THE WELL TOLD COMPANY INC. ("WLCO.H")

LITT:CC
The Conversation (0)
Tryptamine Therapeutics Limited

Successful Maiden Dosing of TRP-8803 (IV-Infused Psilocin) Completed in Global First

Tryptamine Therapeutics Limited (‘Tryp’ or the ‘Company’) (ASX: TYP), a clinical-stage biotechnology company focused on the development of an innovative and scalable intravenous-infused psilocin formulation which may be used in conjunction with psychotherapy to address significant unmet medical needs, is pleased to advise that it has successfully and safely completed the world’s first participant dosing using TRP-8803 (IV-infused psilocin) in a patient in Adelaide, South Australia.

Keep reading...Show less
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension  of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies

  • Bexicaserin achieved an overall median seizure reduction of 56.1% in countable motor seizures over an approximate 6-month treatment period; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%
  • Favorable safety and tolerability results observed
  • 100% of participants who completed the PACIFIC Study entered the OLE
  • End of Phase 2 Meeting scheduled for this summer

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the PACIFIC Study evaluating bexicaserin (LP352) in participants ages 12-65 years old with Developmental and Epileptic Encephalopathies.

"We are thrilled to see a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEE patients. Additionally, we saw compelling seizure reduction in the PACIFIC placebo patients who transitioned to bexicaserin in the OLE. These data provide further support to bexicaserin's potential to offer a highly differentiated and best-in-class profile," stated Dr. Randall Kaye, Longboard's Chief Medical Officer.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver  in Milan

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver in Milan

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models

Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 13,001,120 shares of its common stock at a price to the public of $6.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,000,000 shares of common stock at a purchase price of $6.249 per share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (INKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.

To participate in the Annual Shareholders Meeting, shareholders should visit www.virtualshareholdermeeting.com/INKT2024 and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study

EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×